ALX Oncology Charts Aggressive Path Forward, Fueled by $150M Raise and Focused Pipeline

REDWOOD CITY, Calif. – At a recent investor briefing, ALX Oncology (NASDAQ: ALXO) executives laid out a streamlined, capital-efficient roadmap, centering the company's near-term future on two promising oncology candidates. The strategy is backed by a newly secured $150 million financing round, extending the biotech's cash runway well into 2028.

"We are hyper-focused on execution over the next 18 to 24 months," stated CEO Jason Lettmann. The goal, he emphasized, is to advance both the CD47-blocking agent evorpacept and the EGFR-targeted antibody-drug conjugate ALX2004 to a stage where they are ready for pivotal trials by the end of next year.

The financing provides a crucial cushion as ALX navigates a competitive landscape. Evorpacept, designed to block the "don't eat me" signal on cancer cells with a modified, inactive Fc region to avoid toxicities seen in earlier CD47 approaches, is now being directed at a high-need population: HER2-positive breast cancer patients who have progressed on AstraZeneca and Daiichi Sankyo's blockbuster therapy, Enhertu (trastuzumab deruxtecan).

Chief Medical Officer Dr. Barbara Klencke, presenting updated clinical data, positioned this as a critical unmet need. "Once Enhertu moved into the first-line setting, the efficacy bar in later lines has become significantly higher," she noted. Early data from a combination study of evorpacept with the bispecific antibody zanidatamab showed a 56% objective response rate in heavily pre-treated patients, with signals suggesting efficacy may be linked to CD47 overexpression.

This biomarker hypothesis is now being formally tested in the ongoing ASPEN-09 trial, which has expanded enrollment and will specifically analyze response rates in the CD47-overexpressing subgroup. "We are moving with precision, not just empiricism," Dr. Klencke added.

Meanwhile, ALX2004 represents the company's foray into the crowded but lucrative ADC arena. The in-house program uses a proprietary EGFR antibody aimed at mitigating severe skin toxicities—a common dose-limiting issue with this class—paired with a high-potency TOPO1 inhibitor payload. The Phase I dose-escalation study is currently enrolling patients with EGFR-overexpressing solid tumors, with initial safety data expected later this year.

Analyst & Investor Commentary:

"This is a sensible, do-or-die focus for ALX," said Michael R. Chen, a biotech portfolio manager at Horizon Capital. "The market had questions about their direction. Putting the $150M behind two clear shots on goal, especially in a defined post-Enhertu niche, gives them a credible narrative. The biomarker-driven strategy for evorpacept could be a key differentiator."

"The data in HER2+ breast cancer is intriguing, but let's not get ahead of ourselves," commented Dr. Sarah Elwood, an independent oncology consultant. "A 56% ORR in a small, late-line study is promising, but ASPEN-09 is the real test. As for ALX2004, claiming a better toxicity profile is table stakes in EGFR ADC development; they'll need compelling clinical efficacy to stand out."

"$150M just to run two early-stage programs until 2028? That's not a runway, that's a crawlway," argued David K. Miller, a vocal critic on biotech investing forums. "This feels like a retreat, not a strategy. They're betting the farm on a CD47 biomarker that's still being defined, while their ADC is years behind leaders. The financing saves them from immediate peril but doesn't instill confidence in a breakthrough."

Lettmann acknowledged the competitive environment but expressed confidence. The strengthened balance sheet, he noted, provides operational flexibility and positions ALX for potential partnership discussions, similar to its existing collaboration with Sanofi for evorpacept in multiple myeloma.

For investors, the coming 18 months will be decisive. The company must demonstrate that evorpacept's biomarker hypothesis holds in a controlled trial and that ALX2004 can safely deliver its potent payload. Success on either front could redefine ALX's trajectory in the immuno-oncology space.